Shanghai Pharmaceuticals Subsidiary Gets Production Approval for Clevidipine Injectable Emulsion

南方财经网··CN·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Shanghai Pharmaceuticals announced that its subsidiary, Shanghai First Biochemical Pharmaceutical, has received a Drug Registration Certificate from the National Medical Products Administration for Clevidipine Injectable Emulsion, granting approval for production. The product is available in 50 ml: 25 mg and 100 ml: 50 mg specifications, registered as a Category 3 chemical drug, with the company having invested approximately 52.2 million yuan in research and development. The product is indicated for hypertensive patients who cannot take oral medication. In 2025, hospital procurement of injectable calcium channel blockers with the same mechanism in mainland China reached 911.39 million yuan. Following approval, the product is expected to benefit from medical insurance payment support, increase market share, and enhance the company's competitiveness.

Impact on assets 1

Others▲

Off-coverage companies 1

Shanghai SPH First Biochemical Pharmaceutical Co Ltdi
Private▲ PositiveRegulationrelevance

Shanghai First Biochemical Pharmaceutical received NMPA production approval for Clevidipine Injectable Emulsion after ~52.2 million yuan R&D investment.